{"disease":{"id":"primary-biliary-cholangitis","name":"primary biliary cholangitis"},"drugs":{"marketed":[{"drug_id":"seladelpar","indication_name":"Primary Biliary Cholangitis (PBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Livdelzi","generic_name":"SELADELPAR","company_name":"Gilead Sciences Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":64,"revenue":"200","mechanism":"Livdelzi works by inhibiting the activity of a specific enzyme involved in the progression of liver disease."},{"drug_id":"seladelpar","indication_name":"primary biliary cholangitis (PBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Livdelzi","generic_name":"SELADELPAR","company_name":"Gilead Sciences Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":64,"revenue":"200","mechanism":"Livdelzi works by inhibiting the activity of a specific enzyme involved in the progression of liver disease."},{"drug_id":"elafibranor","indication_name":"Primary biliary cholangitis (PBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Iqirvo","generic_name":"ELAFIBRANOR","company_name":"Ipsen","drug_phase":"marketed","molecular_target":"","drug_class":"Peroxisome Proliferator-activated Receptor Agonist [EPC]","quality_score":60,"revenue":null,"mechanism":"Iqirvo works by activating peroxisome proliferator-activated receptors to improve liver function."}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05151809","title":"National Database on Primary Biliary Cholangitis","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"University of Milano Bicocca","has_results":false},{"nct_id":"NCT05292872","title":"Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients","phase":"","overall_status":"COMPLETED","enrollment_count":4577,"lead_sponsor_name":"Intercept Pharmaceuticals","has_results":true},{"nct_id":"NCT07149675","title":"PBC Long-term Outcomes Study","phase":"","overall_status":"RECRUITING","enrollment_count":4000,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT07449793","title":"Biochemical Response and Clinical Outcomes in Patients With PBC","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT05786482","title":"Evidence Based Mental Wellness Programming Online for Adults Across Chronic Physical Conditions","phase":"NA","overall_status":"COMPLETED","enrollment_count":825,"lead_sponsor_name":"University of Alberta","has_results":false},{"nct_id":"NCT03146910","title":"Swiss Primary Biliary Cholangitis Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Fondazione Epatocentro Ticino","has_results":false},{"nct_id":"NCT05919433","title":"Detection Program for Patients With Primary Biliary Cholangitis Lost in the System","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Hospital Mutua de Terrassa","has_results":false},{"nct_id":"NCT06447168","title":"A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment","phase":"","overall_status":"RECRUITING","enrollment_count":424,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT03322943","title":"The Comparison About the Response of Ursodeoxycholic Acid in Primary Biliary Cholangitis Only and Primary Biliary Cholangitis With High Immune Globulin G or Aminotransferase at West China Hospital","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT06016842","title":"A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":276,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT03602560","title":"ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":265,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT06591468","title":"A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis Characteristics","phase":"PHASE2, PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":244,"lead_sponsor_name":"Han Ying","has_results":false},{"nct_id":"NCT05133336","title":"Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":196,"lead_sponsor_name":"Zydus Therapeutics Inc.","has_results":false},{"nct_id":"NCT04620733","title":"RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":193,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT06427395","title":"Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Zydus Therapeutics Inc.","has_results":false},{"nct_id":"NCT05751967","title":"Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Xijing Hospital of Digestive Diseases","has_results":false},{"nct_id":"NCT04618575","title":"Ursodeoxycholic Acid Combined With Total Glucosides of Paeony in the Treatment of PBC With AIH Features 1","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":137,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT07282353","title":"A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":135,"lead_sponsor_name":"Cascade Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT07296458","title":"FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Xijing Hospital of Digestive Diseases","has_results":false},{"nct_id":"NCT03545672","title":"Early Identification of Myocardial Impairment in PBC","phase":"","overall_status":"COMPLETED","enrollment_count":119,"lead_sponsor_name":"RenJi Hospital","has_results":true},{"nct_id":"NCT05450887","title":"Efficacy and Safety of Obeticholic Acid in the Treatment of Primary Biliary Cholangitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":108,"lead_sponsor_name":"Nanjing Chia-tai Tianqing Pharmaceutical","has_results":false},{"nct_id":"NCT05749822","title":"Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":104,"lead_sponsor_name":"Xijing Hospital of Digestive Diseases","has_results":false},{"nct_id":"NCT05190523","title":"Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":98,"lead_sponsor_name":"Gannex Pharma Co., Ltd.","has_results":false},{"nct_id":"NCT04617561","title":"Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":90,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT04376528","title":"Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Due to Nonresponse to Standard Therapy","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":89,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT07304843","title":"A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":84,"lead_sponsor_name":"Umecrine Cognition AB","has_results":false},{"nct_id":"NCT05014672","title":"A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"Calliditas Therapeutics Suisse SA","has_results":true},{"nct_id":"NCT05896124","title":"CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":75,"lead_sponsor_name":"Cascade Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT04594694","title":"Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":75,"lead_sponsor_name":"Intercept Pharmaceuticals","has_results":false},{"nct_id":"NCT05239468","title":"Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Intercept Pharmaceuticals","has_results":false},{"nct_id":"NCT02943447","title":"Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":71,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT06383403","title":"A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":69,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT03394924","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Enanta Pharmaceuticals, Inc","has_results":true},{"nct_id":"NCT07161245","title":"RELIEF: Multimodal Prehabilitation to Treat Fatigue in Patients With Primary Biliary Cholangitis","phase":"NA","overall_status":"RECRUITING","enrollment_count":64,"lead_sponsor_name":"Hospital Clinic of Barcelona","has_results":false},{"nct_id":"NCT06488911","title":"To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":63,"lead_sponsor_name":"Intercept Pharmaceuticals","has_results":false},{"nct_id":"NCT02516605","title":"A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06371196","title":"Clinical Study on the Treatment of Elevated Total Bilirubin in Primary Biliary Cholangitis With Baobao Dan Capsule","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Mei Han","has_results":false},{"nct_id":"NCT03521297","title":"Probiotics in PBC Patients of Poor Response to UDCA","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06309589","title":"The Effectiveness of Combining Ursodeoxycholic Acid With Vitamin D in Treating Patients With Primary Biliary Cholangitis","phase":"NA","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Yilihamu·Abilitifu","has_results":false},{"nct_id":"NCT03188146","title":"Performance of Scoring Systems in Chinese Patients With Primary Biliary Cholangitis (PBC) on Ursodeoxycholic Acid","phase":"","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Humanity and Health Research Centre","has_results":false},{"nct_id":"NCT03124108","title":"Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Genfit","has_results":true},{"nct_id":"NCT05104853","title":"Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"COUR Pharmaceutical Development Company, Inc.","has_results":false},{"nct_id":"NCT03345589","title":"A Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT06733519","title":"TH104 for the Treatment of Pruritus in Primary Biliary Cholangitis","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Tharimmune Inc","has_results":false},{"nct_id":"NCT03954327","title":"Combination Antiretroviral Therapy (cART) for PBC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"University of Alberta","has_results":false},{"nct_id":"NCT05624294","title":"Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS0159 in Chinese Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Cascade Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT04265235","title":"EXerCise Intervention in cholesTatic LivEr Disease: The EXCITED Study","phase":"NA","overall_status":"TERMINATED","enrollment_count":31,"lead_sponsor_name":"University of Birmingham","has_results":false},{"nct_id":"NCT07049887","title":"A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria)","phase":"","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT06591455","title":"A Pilot Study of Fenofibrate and Ursodeoxycholic Acid in the Treatment of Newly Diagnosed Primary Biliary Cholangitis","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Han Ying","has_results":false},{"nct_id":"NCT03092765","title":"Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":29,"lead_sponsor_name":"EA Pharma Co., Ltd.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}